Rising CKD cases, advanced biomarkers fuel $4.8b market growth

Market growth is expected to continue through 2034.

The chronic kidney disease (CKD) market in the seven major markets—the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan—reached $4.8b in 2024 and is projected to grow steadily through 2034,  according to DelveInsight Business Research.

In 2024, the 7MM had roughly 82 million prevalent CKD cases and 14.5 million diagnosed cases, with numbers projected to rise due to aging populations.

Current CKD therapies have the opportunity to broaden their approved indications.

Emerging clinical evidence suggests that expanding therapy use could improve outcomes across diverse patient populations, potentially driving significant market growth in the coming decade.

Innovations in biomarkers, including KIM-1 and NGAL, are enabling earlier and more precise detection of CKD compared with traditional methods. These advancements promise timely interventions, which could improve patient outcomes and further influence market dynamics.

Amongst the 7MM, the United States accounts for the largest CKD market, outpacing EU4 countries, the United Kingdom, and Japan.